Single Cell RNAseq to identify subpopulations of glial progenitors in iPSC-derived oligodendroglial lineage cultures

2024 · doi:10.1101/2024.12.18.629204
preprint OA: closed
📄 Open PDF Full text JSON View at publisher
Full text 1,943 characters · extracted from oa-doi-fallback · click to expand
Summary Cellular heterogeneity is a common issue in differentiation protocols of oligodendrocytes (OLs) from human induced pluripotent stem cells. Our previous work described a novel method to generate OLs and highlighted the presence of glial progenitors. Here, we unravel the glial heterogeneity and characterize the response of isolated subpopulations to differentiation. This study provides a novel tool for studying the dynamics of glial development in vitro and on a transcriptomic level. Competing Interest Statement Dr.Bernard is/was a consultant for Calico (2023 to present), Orchard Therapeutics (2023), Passage Bio Inc (2020 to 2022), and Ions (2019). She is/was a site investigator for Alexander's disease trial of Ionia (2021 to present), Metachromatic leukodystrophy of Shire/Takeda (2020 to 2021), Krabbe (2021 to 2023) and GM1 gene therapy trials of Passage Bio (2021 to 2024), GM1 natural history study from the University of Pennsylvania sponsored by Passage Bio (2021 to present) and Adrenoleukodystrophy/ Hematopoietic stem cell transplantation natural history study of Bluebird bio (2019), a site sub-investigator for the MPS II gene therapy trial of Regenxbio (2021 to present) and the MPS II clinical trial of Denali (2022 to present). She has received an unrestricted educational grant from Takeda (2021 to 2022). She serves on the scientific advisory board of the Pelizaeus Merzbacher Foundation, the Yaya Foundation Scientific and Clinical Advisory Council, and is the Chair of the Medical and Scientific Advisory Board of the United Leukodystrophy Foundation. She is a member of the Vanishing White Matter Consortium, H ABC Clinical Advisory Board, MLC Clinical Expert Consortium, and the Char of the POLR3 related (4H) Leukodystrophy Consortium. She is on the editorial boards of Neurology Genetics, Frontiers of Neurology: Neurogenetics, and Journal of Medical Genetics. All other authors have nothing to disclose.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00